MeSH term
Frequency | Condition_Probility | Blotting, Western | 3 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Endometrial Neoplasms/*metabolism/pathology | 2 | 6.0 |
English Abstract | 3 | 0.0 |
Female | 31 | 0.0 |
Humans | 77 | 0.0 |
Time Factors | 4 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Up-Regulation | 2 | 0.0 |
Animals | 33 | 0.0 |
*Antigens, Neoplasm | 6 | 3.0 |
Binding, Competitive | 8 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
*Haptoglobins | 6 | 85.0 |
Kinetics | 5 | 0.0 |
Ligands | 3 | 0.0 |
Protein Binding | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 29 | 0.0 |
Trypanosoma brucei brucei/*metabolism | 2 | 40.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Receptors, Progesterone/drug effects/*genetics | 2 | 100.0 |
Receptors, Progesterone/*genetics | 4 | 18.0 |
Alcohol Oxidoreductases/*metabolism | 2 | 25.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Hyperoxaluria, Primary/*etiology | 2 | 100.0 |
Liver/enzymology | 2 | 0.0 |
NADP/metabolism | 2 | 1.0 |
Research Support, Non-U.S. Gov't | 38 | 0.0 |
Cell Line | 11 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
Structure-Activity Relationship | 9 | 0.0 |
Molecular Sequence Data | 24 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Trypanosoma brucei brucei/*immunology | 2 | 66.0 |
Amino Acid Sequence | 13 | 0.0 |
Comparative Study | 9 | 0.0 |
Models, Molecular | 3 | 0.0 |
Mutagenesis, Site-Directed | 7 | 0.0 |
Progesterone/*metabolism | 3 | 8.0 |
Sequence Alignment | 3 | 0.0 |
Adolescent | 3 | 0.0 |
Adult | 7 | 0.0 |
Aged | 4 | 0.0 |
Aged, 80 and over | 2 | 0.0 |
Male | 9 | 0.0 |
Middle Aged | 6 | 0.0 |
Prognosis | 3 | 0.0 |
Rats | 6 | 0.0 |
Molecular Conformation | 3 | 1.0 |
Receptors, Progesterone/*antagonists & inhibitors | 2 | 66.0 |
Binding Sites | 5 | 0.0 |
Genes, Reporter | 2 | 0.0 |
Hormone Antagonists/metabolism/pharmacology | 2 | 100.0 |
Mifepristone/metabolism/pharmacology | 2 | 66.0 |
Receptors, Progesterone/*chemistry | 2 | 66.0 |
*Saccharomyces cerevisiae Proteins | 3 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Transfection | 12 | 0.0 |
Base Sequence | 20 | 0.0 |
DNA Primers | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Exons | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
Promoter Regions (Genetics) | 4 | 0.0 |
Haptoglobins/metabolism | 2 | 8.0 |
In Vitro | 3 | 0.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Receptors, Androgen/metabolism | 2 | 4.0 |
Receptors, Estrogen/metabolism | 3 | 1.0 |
Phosphorylation | 4 | 0.0 |
Receptors, Progesterone/*metabolism | 8 | 7.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Cells, Cultured | 4 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Hela Cells | 7 | 0.0 |
Mifepristone/*pharmacology | 3 | 12.0 |
Promegestone/metabolism | 3 | 25.0 |
Recombinant Proteins/drug effects/metabolism | 2 | 8.0 |
Saccharomyces cerevisiae/*genetics | 2 | 1.0 |
*Trans-Activation (Genetics) | 4 | 0.0 |
Mice | 5 | 0.0 |
Receptors, Progesterone/*antagonists & inhibitors/metabolism | 2 | 100.0 |
Recombinant Proteins/antagonists & inhibitors/metabolism | 2 | 4.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
*Transcription, Genetic | 4 | 0.0 |
Mifepristone/metabolism | 3 | 50.0 |
Protein Conformation | 3 | 0.0 |
Transcription, Genetic | 6 | 0.0 |
Haplorhini | 3 | 1.0 |
Mifepristone/pharmacology | 3 | 3.0 |
Cloning, Molecular | 4 | 0.0 |
DNA/*metabolism | 2 | 0.0 |
Molecular Structure | 2 | 0.0 |
Receptors, Progesterone/*genetics/metabolism | 2 | 33.0 |
Cattle | 2 | 0.0 |
Uterus/metabolism | 3 | 8.0 |
Anisoles/*pharmacology | 2 | 100.0 |
Gene Expression | 3 | 0.0 |
Promegestone/pharmacology | 3 | 18.0 |
Receptors, Steroid/*metabolism | 2 | 3.0 |
*Bacterial Proteins | 2 | 1.0 |
Crystallography, X-Ray | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Software | 2 | 0.0 |
Chickens | 2 | 0.0 |
Receptors, Progesterone/metabolism | 3 | 1.0 |
Sheep | 2 | 0.0 |
Progesterone/pharmacology | 2 | 1.0 |
Pregnancy | 4 | 0.0 |
Progesterone/*pharmacology | 2 | 2.0 |
Rabbits | 2 | 0.0 |
Rats, Wistar | 2 | 0.0 |
*DNA-Binding Proteins | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Injections, Intravenous | 2 | 0.0 |
Gonanes/pharmacology | 2 | 33.0 |
Mifepristone/analogs & derivatives/pharmacology | 2 | 100.0 |
Mammary Tumor Virus, Mouse/genetics | 2 | 5.0 |
Mifepristone/analogs & derivatives/*pharmacology | 2 | 100.0 |
Chloramphenicol O-Acetyltransferase/genetics/metabolism | 2 | 1.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Progesterone/*antagonists & inhibitors | 2 | 100.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Depression, Chemical | 2 | 1.0 |
Receptors, Progesterone/*drug effects/genetics/metabolism | 2 | 66.0 |
Stimulation, Chemical | 2 | 0.0 |
DNA/genetics | 2 | 0.0 |
*Promoter Regions (Genetics) | 3 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Restriction Mapping | 5 | 0.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Prolactin/*blood | 2 | 0.0 |
Breast Neoplasms/analysis | 2 | 28.0 |
Species Specificity | 2 | 0.0 |
Mastectomy | 2 | 2.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Haptoglobins/*genetics | 3 | 7.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Progesterone/metabolism | 2 | 2.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Prolactin/blood | 2 | 0.0 |
Radioimmunoassay | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Prolactin/*secretion | 2 | 1.0 |
Estrogens/metabolism | 2 | 2.0 |